Alt, Marie
Stecca, Carlos
Lin, Yian
Kazeem, Gbenga
Goluboff, Erik T.
Sridhar, Srikala S.
Funding for this research was provided by:
AstraZeneca USA
Article History
Received: 9 January 2023
Accepted: 5 September 2023
First Online: 29 September 2023
Declarations
:
: This is a post hoc analysis of data previously collected from clinical studies (Study 1108 and Study 10). The data involved included demographic, survival data and tumor response. Data was already available for analysis, with no new data collected from the patients and thus the original study consent forms covered this analysis. The inclusion of patients’ data in this post hoc analysis was allowed under the Study 1108 and Study 10 consent forms. Study 1108 and Study 10 were conducted according to the Declaration of Helsinki and approved by the independent ethics committee or institutional review board at each of the participating centres, with written informed consent obtained from all patients.
: Not applicable.
: MA and CS have no disclosures to report. YL is a current employee of AstraZeneca. GK and ETG were employed by AstraZeneca during the time of the study. SSS reports consulting/advisory for Pfizer, EMD Serono, Merck, Roche, Bristol Myers Squibb, AstraZeneca, Immunomedics, Seagen, Astellas, Janssen, Bayer.